FR08C0028I2 - - Google Patents

Info

Publication number
FR08C0028I2
FR08C0028I2 FR08C0028C FR08C0028C FR08C0028I2 FR 08C0028 I2 FR08C0028 I2 FR 08C0028I2 FR 08C0028 C FR08C0028 C FR 08C0028C FR 08C0028 C FR08C0028 C FR 08C0028C FR 08C0028 I2 FR08C0028 I2 FR 08C0028I2
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR08C0028C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26305774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR08C0028(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB9420425A external-priority patent/GB9420425D0/en
Priority claimed from GBGB9508745.8A external-priority patent/GB9508745D0/en
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of FR08C0028I1 publication Critical patent/FR08C0028I1/fr
Application granted granted Critical
Publication of FR08C0028I2 publication Critical patent/FR08C0028I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR08C0028C 1994-10-07 2008-06-27 Active FR08C0028I2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9420425A GB9420425D0 (en) 1994-10-07 1994-10-07 New compound
GBGB9508745.8A GB9508745D0 (en) 1995-04-28 1995-04-28 New compound
PCT/JP1995/001983 WO1996011210A1 (en) 1994-10-07 1995-09-29 Cyclic hexapeptides having antibiotic activity

Publications (2)

Publication Number Publication Date
FR08C0028I1 FR08C0028I1 (enExample) 2008-08-15
FR08C0028I2 true FR08C0028I2 (enExample) 2009-11-20

Family

ID=26305774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR08C0028C Active FR08C0028I2 (enExample) 1994-10-07 2008-06-27

Country Status (26)

Country Link
US (2) US6107458A (enExample)
EP (1) EP0788511B1 (enExample)
JP (2) JP2897427B2 (enExample)
KR (1) KR100353303B1 (enExample)
CN (1) CN1203089C (enExample)
AR (1) AR041770A1 (enExample)
AT (1) ATE229541T1 (enExample)
AU (1) AU696949B2 (enExample)
BR (2) BRPI9504791B8 (enExample)
CA (1) CA2202058C (enExample)
DE (2) DE69529172T2 (enExample)
DK (1) DK0788511T3 (enExample)
ES (1) ES2187575T3 (enExample)
FI (1) FI119988B (enExample)
FR (1) FR08C0028I2 (enExample)
HU (1) HU228151B1 (enExample)
IL (1) IL115484A (enExample)
LU (1) LU91452I2 (enExample)
MX (1) MX9702531A (enExample)
NL (1) NL300352I2 (enExample)
NO (2) NO328483B1 (enExample)
OA (1) OA10475A (enExample)
PT (1) PT788511E (enExample)
RU (1) RU2165423C2 (enExample)
TR (1) TR199501229A2 (enExample)
WO (1) WO1996011210A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696084A (en) * 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
AUPO371596A0 (en) * 1996-11-19 1996-12-12 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPO381496A0 (en) * 1996-11-25 1996-12-19 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1998057923A1 (en) * 1997-06-18 1998-12-23 Fujisawa Pharmaceutical Co., Ltd. New production process
AU756792B2 (en) * 1998-02-09 2003-01-23 Fujisawa Pharmaceutical Co., Ltd. New compound
WO1999040108A1 (en) * 1998-02-09 1999-08-12 Fujisawa Pharmaceutical Co., Ltd. New compound
WO2000047188A1 (en) * 1999-02-11 2000-08-17 Emisphere Technologies, Inc. Oxadiazole compounds and compositions for delivering active agents
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
AUPP999799A0 (en) 1999-04-27 1999-05-20 Fujisawa Pharmaceutical Co., Ltd. New compound
AUPQ066399A0 (en) 1999-05-31 1999-06-24 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
TWI233805B (en) * 1999-07-01 2005-06-11 Fujisawa Pharmaceutical Co Stabilized pharmaceutical composition in lyophilized form as antifungal agent
ATE416189T1 (de) 1999-07-27 2008-12-15 Aventis Pharma Gmbh Cyclohexapeptide, deren herstellung und verwendung in pharmazeutische zusammensetzungen
AUPQ462399A0 (en) * 1999-12-13 2000-01-13 Fujisawa Pharmaceutical Co., Ltd. New use
TWI250992B (en) * 2000-02-21 2006-03-11 Astellas Pharma Inc Polypeptide compounds for the prophylactic and/or therapeutic treatment of infectious diseases caused by pathogenic microorganisms
ES2191516B1 (es) * 2000-07-28 2005-01-01 Consejo Superior De Investigaciones Cientificas Antibioticos antifungicos de naturaleza peptidica inhibidores de la germinacion y el crecimiento de hongos fitopatogenos.
AUPQ938700A0 (en) * 2000-08-14 2000-09-07 Fujisawa Pharmaceutical Co., Ltd. Antifungal combination use
DE60234812D1 (de) 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
JP2005053782A (ja) * 2001-08-31 2005-03-03 Fujisawa Pharmaceut Co Ltd 環状リポペプチド化合物の新規結晶
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2004014879A1 (en) * 2002-08-08 2004-02-19 Fujisawa Pharmaceutical Co., Ltd. New process
AU2003903205A0 (en) * 2003-06-23 2003-07-10 Fujisawa Pharmaceutical Co., Ltd. New compound
EP1654036B1 (en) * 2003-07-22 2007-12-26 Theravance, Inc. Use of an echinocandin antifungal agent in combination with a glycopeptide antibacterial agent
JP2007504460A (ja) * 2003-09-05 2007-03-01 メルク エンド カムパニー インコーポレーテッド 固定相及び該固定相を用いた精製プロセス
WO2005028438A1 (ja) * 2003-09-22 2005-03-31 Banyu Pharmaceutical Co., Ltd. 新規ピペリジン誘導体
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
WO2005112913A1 (en) * 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
JP2008515992A (ja) * 2004-10-13 2008-05-15 ピーティーシー セラピューティクス,インコーポレーテッド 体細胞変異に起因する疾患の阻止/治療用医薬を製造するための規定化合物の使用
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
CA2623327A1 (en) * 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
CN101516387B (zh) * 2006-07-26 2014-06-04 桑多斯股份公司 卡泊芬净制剂
US8853392B2 (en) 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
ES2655466T3 (es) 2007-08-13 2018-02-20 Monsanto Technology Llc Composiciones y procedimientos de control de nematodos
JPWO2009057568A1 (ja) * 2007-10-29 2011-03-10 アステラス製薬株式会社 ポリペプチド化合物
US8034806B2 (en) 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
WO2010008831A2 (en) * 2008-06-24 2010-01-21 Irm Llc Compounds and methods for modulating g protein-coupled receptors
US9394340B2 (en) 2009-03-24 2016-07-19 Cadila Healthcare Limited Purification process for lipopeptides
BR112013023531A2 (pt) * 2011-04-04 2016-12-06 Xellia Pharmaceuticals Aps processo de um único vaso para a fabricação de micafungina ou de um sal desta
HUE027806T2 (en) 2011-04-20 2016-11-28 Xellia Pharmaceuticals Aps A method for purifying micafungin
CN102775476B (zh) 2011-05-12 2015-01-07 上海天伟生物制药有限公司 一种米卡芬净钠盐的制备方法
JP6130827B2 (ja) 2011-05-17 2017-05-17 塩野義製薬株式会社 ヘテロ環化合物
WO2013034670A1 (en) 2011-09-09 2013-03-14 Sandoz Ag Preparation of micafungin intermediates
CN102659930B (zh) * 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627688B (zh) 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
CN102627689B (zh) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
WO2015180681A1 (zh) * 2014-05-29 2015-12-03 上海天伟生物制药有限公司 一种环肽类化合物的组合物及其制备方法和用途
CN104861044B (zh) * 2014-05-29 2019-03-01 上海天伟生物制药有限公司 一种环肽类化合物的溶剂合物及其制备方法和用途
EP3226885A4 (en) * 2014-10-07 2018-07-18 Alaparthi, Lakshmi Prasad Intermediates and processes to prepare micafungin
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
PT3554474T (pt) 2016-12-16 2024-02-12 Baxter Healthcare Sa Composições de micafungina
EP3485873A1 (en) 2017-11-17 2019-05-22 Cadila Healthcare Limited Stable pharmaceutical injectable compositions of micafungin
CN113087775B (zh) * 2018-05-31 2022-07-08 杭州中美华东制药有限公司 米卡芬净钠新晶型ii及其制备方法
WO2020013116A1 (ja) * 2018-07-10 2020-01-16 京都薬品工業株式会社 Ptp-1b阻害剤およびその用途
CN110734408A (zh) * 2019-10-22 2020-01-31 重庆康乐制药有限公司 一种米卡芬净类衍生物侧链中间体的制备方法
CN115785226B (zh) * 2021-09-09 2026-02-24 上海天伟生物制药有限公司 一种棘白菌素药物杂质及其制备、纯化方法和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1574603A1 (ru) * 1988-08-11 1990-06-30 Ивановский Химико-Технологический Институт Способ получени мезо-тетраарилоктаметилпорфиринов
IL98506A (en) * 1990-06-18 1996-09-12 Fujisawa Pharmaceutical Co Cyclic peptide antibiotics processes for the preparation thereof and pharmaceutical compositions containing them
MY136593A (en) * 1992-03-19 2008-10-31 Lilly Co Eli Cyclic peptide antifungal agents and process for preparation thereof

Also Published As

Publication number Publication date
BRPI9504791B8 (pt) 2019-12-31
WO1996011210A1 (en) 1996-04-18
HU228151B1 (en) 2012-12-28
NO971544D0 (no) 1997-04-04
JP3518665B2 (ja) 2004-04-12
EP0788511A1 (en) 1997-08-13
HK1004136A1 (en) 1998-11-20
FI971397L (fi) 1997-05-27
JP2897427B2 (ja) 1999-05-31
IL115484A0 (en) 1996-01-19
DE69529172D1 (de) 2003-01-23
PT788511E (pt) 2003-04-30
FI119988B (fi) 2009-05-29
FR08C0028I1 (enExample) 2008-08-15
FI971397A0 (fi) 1997-04-04
LU91452I2 (fr) 2008-08-04
CN1203089C (zh) 2005-05-25
AU696949B2 (en) 1998-09-24
CA2202058C (en) 2007-11-06
OA10475A (en) 2002-04-08
DE122008000025I2 (de) 2011-02-17
DE69529172T2 (de) 2003-04-17
EP0788511B1 (en) 2002-12-11
IL115484A (en) 2000-07-16
DK0788511T3 (da) 2003-03-31
JPH10507174A (ja) 1998-07-14
BR9504791B1 (pt) 2010-10-05
US6265536B1 (en) 2001-07-24
NO2010016I1 (no) 2010-08-16
JPH10324695A (ja) 1998-12-08
AU3578095A (en) 1996-05-02
ATE229541T1 (de) 2002-12-15
KR970707150A (ko) 1997-12-01
US6107458A (en) 2000-08-22
RU2165423C2 (ru) 2001-04-20
HUT77736A (hu) 1998-07-28
DE122008000025I1 (de) 2008-08-21
CA2202058A1 (en) 1996-04-18
NO971544L (no) 1997-06-04
NO2010016I2 (no) 2011-10-17
AR041770A1 (es) 2005-06-01
MX9702531A (es) 1997-06-28
NL300352I1 (nl) 2008-08-01
BR9504791A (pt) 1996-10-22
ES2187575T3 (es) 2003-06-16
KR100353303B1 (ko) 2003-01-15
NO328483B1 (no) 2010-03-01
NL300352I2 (nl) 2008-11-03
TR199501229A2 (tr) 1996-07-21
CN1168675A (zh) 1997-12-24

Similar Documents

Publication Publication Date Title
TW278172B (enExample)
TW285654B (enExample)
DK105996A (enExample)
FR08C0028I1 (enExample)
EP0666525A3 (enExample)
EP0666470A3 (enExample)
EP0665261A3 (enExample)
EP0667627A3 (enExample)
EP0670326A3 (enExample)
BR9509661A (enExample)
TW279989B (enExample)
FR2725446B1 (enExample)
FR2725734B1 (enExample)
ITBZ950004V0 (enExample)
FR2728521B1 (enExample)
BR7402039U (enExample)
ECSDI940181S (enExample)
ECSMU940034U (enExample)
ECSMU940030U (enExample)
EP0662420A3 (enExample)
CU22453A3 (enExample)
ECSDI940185S (enExample)
BR7402097U (enExample)
DK40195A (enExample)
IN189349B (enExample)